These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10531220)

  • 21. Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.
    Gamage SD; McGannon CM; Weiss AA
    J Bacteriol; 2004 Aug; 186(16):5506-12. PubMed ID: 15292153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.
    Lindgren SW; Samuel JE; Schmitt CK; O'Brien AD
    Infect Immun; 1994 Feb; 62(2):623-31. PubMed ID: 8300218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.
    Tesh VL; Burris JA; Owens JW; Gordon VM; Wadolkowski EA; O'Brien AD; Samuel JE
    Infect Immun; 1993 Aug; 61(8):3392-402. PubMed ID: 8335369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins.
    Pruimboom-Brees IM; Morgan TW; Ackermann MR; Nystrom ED; Samuel JE; Cornick NA; Moon HW
    Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10325-9. PubMed ID: 10973498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.
    Bentancor LV; Bilen M; Brando RJ; Ramos MV; Ferreira LC; Ghiringhelli PD; Palermo MS
    Clin Vaccine Immunol; 2009 May; 16(5):712-8. PubMed ID: 19176691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.
    Tremblay JM; Mukherjee J; Leysath CE; Debatis M; Ofori K; Baldwin K; Boucher C; Peters R; Beamer G; Sheoran A; Bedenice D; Tzipori S; Shoemaker CB
    Infect Immun; 2013 Dec; 81(12):4592-603. PubMed ID: 24082082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.
    Rocha LB; Luz DE; Moraes CT; Caravelli A; Fernandes I; Guth BE; Horton DS; Piazza RM
    Toxins (Basel); 2012 Sep; 4(9):729-47. PubMed ID: 23105978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins.
    Liu J; Sun Y; Feng S; Zhu L; Guo X; Qi C
    Vaccine; 2009 Oct; 27(43):5929-35. PubMed ID: 19682616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Escherichia coli Isolates from humans, food, and farm and companion animals for presence of Shiga toxin-producing E. coli virulence markers.
    Murinda SE; Nguyen LT; Landers TL; Draughon FA; Mathew AG; Hogan JS; Smith KL; Hancock DD; Oliver SP
    Foodborne Pathog Dis; 2004; 1(3):178-84. PubMed ID: 15992278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.
    Ashkenazi S; Cleary TG
    J Clin Microbiol; 1989 Jun; 27(6):1145-50. PubMed ID: 2666433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.
    Boyd B; Richardson S; Gariepy J
    Infect Immun; 1991 Mar; 59(3):750-7. PubMed ID: 1705242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity.
    Shimizu T; Sato T; Kawakami S; Ohta T; Noda M; Hamabata T
    Microb Pathog; 2007; 43(2-3):88-95. PubMed ID: 17532600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.
    Ludwig K; Sarkim V; Bitzan M; Karmali MA; Bobrowski C; Ruder H; Laufs R; Sobottka I; Petric M; Karch H; Müller-Wiefel DE
    J Clin Microbiol; 2002 May; 40(5):1773-82. PubMed ID: 11980959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vero toxins (Shiga-like toxins) produced by enterohemorrhagic Escherichia coli (verocytotoxin-producing E. coli).
    Takeda Y; Kurazono H; Yamasaki S
    Microbiol Immunol; 1993; 37(8):591-9. PubMed ID: 8246822
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.
    Jeong KI; Chapman-Bonofiglio S; Singh P; Lee J; Tzipori S; Sheoran AS
    BMC Immunol; 2010 Mar; 11():16. PubMed ID: 20334660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.
    Fraser ME; Fujinaga M; Cherney MM; Melton-Celsa AR; Twiddy EM; O'Brien AD; James MN
    J Biol Chem; 2004 Jun; 279(26):27511-7. PubMed ID: 15075327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity.
    Albanese A; Sacerdoti F; Seyahian EA; Amaral MM; Fiorentino G; Fernandez Brando R; Vilte DA; Mercado EC; Palermo MS; Cataldi A; Zotta E; Ibarra C
    Vaccine; 2018 Mar; 36(13):1728-1735. PubMed ID: 29483033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli.
    Luz D; Chen G; Maranhão AQ; Rocha LB; Sidhu S; Piazza RM
    PLoS One; 2015; 10(3):e0120481. PubMed ID: 25790467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses.
    Su GF; Brahmbhatt HN; Wehland J; Rohde M; Timmis KN
    Infect Immun; 1992 Aug; 60(8):3345-59. PubMed ID: 1639503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.
    Takeda T; Yoshino K; Adachi E; Sato Y; Yamagata K
    Microbiol Immunol; 1999; 43(4):331-7. PubMed ID: 10385199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.